Pesquisar
Alnylam Pharmaceuticals Inc
ALNYAdicionar à lista de desejos
293.520USD
+2.150+0.74%
Fechamento 06/29, 16:00（ET）Cotações atrasadas em 15 min
39.17BValor de mercado
71.84P/L TTM
Mais detalhes de Alnylam Pharmaceuticals Inc Empresa
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Informações de Alnylam Pharmaceuticals Inc
Código da empresaALNY
Nome da EmpresaAlnylam Pharmaceuticals Inc
Data de listagemMay 28, 2004
CEOGreenstreet (Yvonne L)
Número de funcionários2230
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 28
Endereço675 W Kendall St
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142-1168
Telefone16175518200
Sitehttps://www.alnylam.com/
Código da empresaALNY
Data de listagemMay 28, 2004
CEOGreenstreet (Yvonne L)
Executivos da empresa Alnylam Pharmaceuticals Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
671.00
--
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
56.38K
+7.29%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
39.68K
+0.24%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
15.33K
+5.62%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.31K
+15.58%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
807.00
+83.15%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
671.00
--
Perguntas frequentes
Quem são os cinco principais acionistas de Alnylam Pharmaceuticals Inc?
Os cinco principais acionistas de Alnylam Pharmaceuticals Inc são: Dr. Yvonne L. Greenstreet, M.D.
Quantas instituições possuem ações da Alnylam Pharmaceuticals Inc (ALNY)?
Em 2026Q1, 1634 instituições possuíam ações da Alnylam Pharmaceuticals Inc, com valor de mercado aproximado de 133.66M, representando 100.11% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -6052832.00.
Qual é a maior fonte de receita da Alnylam Pharmaceuticals Inc?
Em 2026Q1, o segmento de negócios AMVUTTRA gerou a maior receita para Alnylam Pharmaceuticals Inc, totalizando 2.31B e representando 62.30% da receita total.
